#3064
ALPPS for Neuroendocrine Liver Metastases Not Suitable for Conventional Hepatic Resection - Interim Analysis of the International ALPPS Registry
Introduction:
Surgery is the most effective treatment option for neuroendocrine liver metastases (NELM). However, the majority of patients with NELM do not have disease that is resectable using conventional methods. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a relatively novel two-stage strategy in hepatic surgery.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Frilling A
Authors:
Linecker M,
Kambakamba P,
Raptis D,
Malago M,
Ratti F,
Keywords:
neuroendocrine,
liver,
metastases,
surgery,
ALPPS,
two-stage,
resection,
#3058
Diagnosis and Assessment of Effectiveness of Surgical Resection of Small Bowel Neuroendocrine Tumours: The Roles of Circulating MicroRNAs
Introduction:
MicroRNAs (miRNA) are small noncoding RNA molecules implicated in the pathophysiology of myriad neoplasms. Clinically useful biomarkers are needed in SB NET to ascertain disease aggressiveness, select treatment strategy, detect early recurrence and monitor response.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Clift A
Authors:
Malczewska A,
Frampton A,
Prado M,
Ameri S,
Dabrowska A,
Keywords:
neuroendocrine,
small bowel,
intestine,
microRNA,
biomarker,
#3040
Palliative CT Brachytherapy in Hepatic Metastatic NET
Introduction:
Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Jann H
Authors:
Feldhaus F,
Jann H,
Jonczyk M,
Boening G,
Wieners G,
Keywords:
brachytherapy,
afterloading,
hepatic metastases,
local tumor ablation,
local tumor control,
#3033
First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)
Introduction:
Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Suh M,
Cheon G,
Lee D,
Keywords:
PRRT,
clinical trial,
Neuroendocrine tumor,
Lu-177-DOTATATE,
#3029
Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report
Introduction:
Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Morales Herrero R,
Herrero Rivera D,
Santos Fernández P,
Benavent M,
Keywords:
ACC,
chemotherapy,
mitotane,
local therapy,
